NCT04923126View on ClinicalTrials.gov

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

June 30, 2031

Study Completion Date

June 30, 2031

Conditions
Low-Grade GliomaRecurrent Low-Grade GliomaProgressive Low-Grade Glioma
Interventions
DRUG

Mirdametinib

By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

SpringWorks Therapeutics, Inc.

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER